FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313500504> ?p ?o ?g. }

• W4313500504 endingPage "501" @default.
• W4313500504 startingPage "493" @default.
• W4313500504 abstract "The combination of ponatinib, a third-generation BCR::ABL1 tyrosine kinase inhibitor, with hyper-CVAD chemotherapy resulted in high rates of complete molecular remissions and survival, without the need for stem cell transplantation (SCT) in most patients with Philadelphia chromosome(Ph)-positive acute lymphocytic leukemia (ALL). Confirming these results in a large cohort of patients with longer follow-up would establish this regimen as a new standard of care. Adults with newly diagnosed Ph-positive ALL were treated with the hyper-CVAD regimen. Ponatinib was added as 45 mg daily × 14 during induction, then 45 mg daily continuously (first 37 patients) or 30 mg daily continuously, with dose reduction to 15 mg daily upon achievement of a complete molecular response (CMR; absence of a detectable BCR::ABL1 transcript by quantitative reverse transcription polymerase-chain reaction at a sensitivity of 0.01%). Maintenance therapy consisted of daily ponatinib and vincristine-prednisone monthly for 2 years, followed by daily ponatinib indefinitely. Twelve intrathecal injections of cytarabine alternating with methotrexate were given as central nervous system prophylaxis. The trial is registered on clinicaltrials.gov with the identifier NCT01424982. Eighty-six patients were treated. Their median age was 46 years (range, 21-80). All 68 patients with active disease at the initiation of therapy achieved complete response (CR) The cumulative CMR rate was 86%. Twenty- patients (23%) underwent allogeneic SCT. With a median follow-up of 80 months (range, 16-129 months), the estimated 6-year event-free survival rate was 65% and the overall survival rate was 75%. There was no difference in outcome by performance of allogeneic SCT in first CR. Common grade 3-5 adverse events included infection (n = 80, 93%), increased liver transaminases (n = 26, 31%) and total bilirubin (n = 13, 15%), hypertension (n = 15, 17%), pancreatitis (n = 13, 15%), hemorrhage (n = 12, 13%), and skin rash (n = 9, 10%). Two ponatinib-related deaths from myocardial infarction (3%; at months 2.6 and 4.3, respectively; both in CR) in the first 37 patients treated led to the ponatinib dose-modifications mentioned earlier, with no further ponatinib-related deaths observed. The long-term results of ponatinib and hyper-CVAD continue to demonstrate excellent outcome results and acceptable safety data, indicating that this strategy is another standard of care approach in frontline Ph-positive ALL." @default.
• W4313500504 created "2023-01-06" @default.
• W4313500504 creator A5000750846 @default.
• W4313500504 creator A5006104041 @default.
• W4313500504 creator A5015524203 @default.
• W4313500504 creator A5021380291 @default.
• W4313500504 creator A5028591457 @default.
• W4313500504 creator A5029750735 @default.
• W4313500504 creator A5033737136 @default.
• W4313500504 creator A5043585566 @default.
• W4313500504 creator A5049385583 @default.
• W4313500504 creator A5056317446 @default.
• W4313500504 creator A5057822243 @default.
• W4313500504 creator A5061026876 @default.
• W4313500504 creator A5069176297 @default.
• W4313500504 creator A5069460930 @default.
• W4313500504 creator A5077963154 @default.
• W4313500504 creator A5088307376 @default.
• W4313500504 creator A5089428686 @default.
• W4313500504 creator A5090435894 @default.
• W4313500504 creator A5091492845 @default.
• W4313500504 date "2023-01-04" @default.
• W4313500504 modified "2023-10-15" @default.
• W4313500504 title "Frontline combination of ponatinib and <scp>hyper‐CVAD</scp> in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results" @default.
• W4313500504 cites W1774142096 @default.
• W4313500504 cites W1838408716 @default.
• W4313500504 cites W1972060994 @default.
• W4313500504 cites W1993808217 @default.
• W4313500504 cites W2011186694 @default.
• W4313500504 cites W2030796837 @default.
• W4313500504 cites W2033862877 @default.
• W4313500504 cites W2047597898 @default.
• W4313500504 cites W2056639876 @default.
• W4313500504 cites W2065851457 @default.
• W4313500504 cites W2099616647 @default.
• W4313500504 cites W2102929198 @default.
• W4313500504 cites W2110648386 @default.
• W4313500504 cites W2116522391 @default.
• W4313500504 cites W2123755151 @default.
• W4313500504 cites W2135492799 @default.
• W4313500504 cites W2136334823 @default.
• W4313500504 cites W2137520438 @default.
• W4313500504 cites W2148763134 @default.
• W4313500504 cites W2340233667 @default.
• W4313500504 cites W2344488712 @default.
• W4313500504 cites W2406225326 @default.
• W4313500504 cites W2483008971 @default.
• W4313500504 cites W2559559785 @default.
• W4313500504 cites W2566332174 @default.
• W4313500504 cites W2790671015 @default.
• W4313500504 cites W2809629567 @default.
• W4313500504 cites W2892257538 @default.
• W4313500504 cites W2902317207 @default.
• W4313500504 cites W3093938683 @default.
• W4313500504 cites W3128092404 @default.
• W4313500504 cites W3140975240 @default.
• W4313500504 cites W3194203975 @default.
• W4313500504 cites W4210861756 @default.
• W4313500504 cites W4225972469 @default.
• W4313500504 cites W4229373608 @default.
• W4313500504 cites W4281689171 @default.
• W4313500504 cites W4285390300 @default.
• W4313500504 cites W4309144621 @default.
• W4313500504 doi "https://doi.org/10.1002/ajh.26816" @default.
• W4313500504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36600670" @default.
• W4313500504 hasPublicationYear "2023" @default.
• W4313500504 type Work @default.
• W4313500504 citedByCount "8" @default.
• W4313500504 countsByYear W43135005042022 @default.
• W4313500504 countsByYear W43135005042023 @default.
• W4313500504 crossrefType "journal-article" @default.
• W4313500504 hasAuthorship W4313500504A5000750846 @default.
• W4313500504 hasAuthorship W4313500504A5006104041 @default.
• W4313500504 hasAuthorship W4313500504A5015524203 @default.
• W4313500504 hasAuthorship W4313500504A5021380291 @default.
• W4313500504 hasAuthorship W4313500504A5028591457 @default.
• W4313500504 hasAuthorship W4313500504A5029750735 @default.
• W4313500504 hasAuthorship W4313500504A5033737136 @default.
• W4313500504 hasAuthorship W4313500504A5043585566 @default.
• W4313500504 hasAuthorship W4313500504A5049385583 @default.
• W4313500504 hasAuthorship W4313500504A5056317446 @default.
• W4313500504 hasAuthorship W4313500504A5057822243 @default.
• W4313500504 hasAuthorship W4313500504A5061026876 @default.
• W4313500504 hasAuthorship W4313500504A5069176297 @default.
• W4313500504 hasAuthorship W4313500504A5069460930 @default.
• W4313500504 hasAuthorship W4313500504A5077963154 @default.
• W4313500504 hasAuthorship W4313500504A5088307376 @default.
• W4313500504 hasAuthorship W4313500504A5089428686 @default.
• W4313500504 hasAuthorship W4313500504A5090435894 @default.
• W4313500504 hasAuthorship W4313500504A5091492845 @default.
• W4313500504 hasConcept C104317684 @default.
• W4313500504 hasConcept C126322002 @default.
• W4313500504 hasConcept C138626823 @default.
• W4313500504 hasConcept C141071460 @default.
• W4313500504 hasConcept C2776694085 @default.
• W4313500504 hasConcept C2776755627 @default.
• W4313500504 hasConcept C2777583451 @default.
• W4313500504 hasConcept C2778041864 @default.

• next